Atamyo Therapeutics proclaimed that the FDA has given the green light for its ATA-100 IND application to advance into a Phase 1b/2b clinical study.

Bcl-2 inhibitors can be used alone to kill cancer cells or can be used in combination with other drugs to increase the sensitivity of cancer cells to drugs.

VBI Vaccines Inc. publicized that its strategic HBV collaborator, Brii Biosciences announced preliminary group-level unmasked 36-week data from a mid-term examination of a randomly assigned, placebo-controlled, and double-concealed Phase 2 investigation of BRII-179 (VBI-2601).

This article summarized the latest R&D progress of Naxitamab, the Mechanism of Action for Naxitamab, and the drug target R&D trends for Naxitamab.

Johnson's Janssen Pharmaceutical Companies have disclosed encouraging preliminary findings from the tri-modality Phase 3 MARIPOSA-2 trial.

The Ataxia telangiectasia and Rad-3 related protein kinase (ATR) is a member of the PIKK protein kinase family, and it is involved in numerous complex DNA damage repair mechanisms.

This article summarized the latest R&D progress of Tucatinib, the Mechanism of Action for Tucatinib, and the drug target R&D trends for Tucatinib.

Genentech, part of the Roche Group, has revealed that the FDA has accepted to their BLA for crovalimab, an exploratory, newly-developed anti-C5 recycling monoclonal antibody.

Janssen is a pharmaceutical company owned by Johnson & Johnson, a multinational company in the global medical device, pharmaceutical and consumer goods sectors.

Beam Therapeutics Inc., a firm in the biotechnology sector focusing on the creation of exact genetic treatments via base editing, declared that the first patient received BEAM-201 treatment.

This article summarized the latest R&D progress of Metyrapone, the Mechanism of Action for Metyrapone, and the drug target R&D trends for Metyrapone.

The Angiotensin II receptor plays a crucial role in the human body by regulating blood pressure and fluid balance.